Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy
Muscular dystrophy and dilated cardiomyopathy are intractable diseases and their treatment options are very limited. Transient receptor potential cation channel subfamily V, member 2 (TRPV2), is a stretch-sensitive Ca<sup>2+</sup>-permeable channel that causes sustained intracellular Ca&...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/16/3844 |
id |
doaj-280a2fd1962147cd850eca1c9e337ee9 |
---|---|
record_format |
Article |
spelling |
doaj-280a2fd1962147cd850eca1c9e337ee92020-11-25T00:56:11ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-08-012016384410.3390/ijms20163844ijms20163844Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular DystrophyYuko Iwata0Tsuyoshi Matsumura1Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, 6-1 Kishibe Shinmachi, Suita, Osaka 564-8565, JapanDepartment of Neurology, National Hospital Organization Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552, JapanMuscular dystrophy and dilated cardiomyopathy are intractable diseases and their treatment options are very limited. Transient receptor potential cation channel subfamily V, member 2 (TRPV2), is a stretch-sensitive Ca<sup>2+</sup>-permeable channel that causes sustained intracellular Ca<sup>2+</sup> increase in muscular cells, which is a pathophysiological feature of degenerative muscular disease. Recent reports have clarified that TRPV2 is concentrated and activated in the sarcolemma of cardiomyocytes/myocytes during cardiomyopathy/heart failure and muscular dystrophy. Furthermore, these reports showed that inactivation of TRPV2 ameliorates muscle dysgenesis to improve cardiac function and survival prognosis. Although TRPV2 is a potential therapeutic target for cardiomyopathy, there were no TRPV2 inhibitors available until recently. In this review, we introduce our recent findings and discuss the current progress in the development of TRPV2 inhibitors and their therapeutic applications for cardiomyopathy associated with muscular dystrophy.https://www.mdpi.com/1422-0067/20/16/3844TRPV2muscular dystrophycardiomyopathyheart failureTRPV2 inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuko Iwata Tsuyoshi Matsumura |
spellingShingle |
Yuko Iwata Tsuyoshi Matsumura Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy International Journal of Molecular Sciences TRPV2 muscular dystrophy cardiomyopathy heart failure TRPV2 inhibitors |
author_facet |
Yuko Iwata Tsuyoshi Matsumura |
author_sort |
Yuko Iwata |
title |
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy |
title_short |
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy |
title_full |
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy |
title_fullStr |
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy |
title_full_unstemmed |
Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy |
title_sort |
blockade of trpv2 is a novel therapy for cardiomyopathy in muscular dystrophy |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-08-01 |
description |
Muscular dystrophy and dilated cardiomyopathy are intractable diseases and their treatment options are very limited. Transient receptor potential cation channel subfamily V, member 2 (TRPV2), is a stretch-sensitive Ca<sup>2+</sup>-permeable channel that causes sustained intracellular Ca<sup>2+</sup> increase in muscular cells, which is a pathophysiological feature of degenerative muscular disease. Recent reports have clarified that TRPV2 is concentrated and activated in the sarcolemma of cardiomyocytes/myocytes during cardiomyopathy/heart failure and muscular dystrophy. Furthermore, these reports showed that inactivation of TRPV2 ameliorates muscle dysgenesis to improve cardiac function and survival prognosis. Although TRPV2 is a potential therapeutic target for cardiomyopathy, there were no TRPV2 inhibitors available until recently. In this review, we introduce our recent findings and discuss the current progress in the development of TRPV2 inhibitors and their therapeutic applications for cardiomyopathy associated with muscular dystrophy. |
topic |
TRPV2 muscular dystrophy cardiomyopathy heart failure TRPV2 inhibitors |
url |
https://www.mdpi.com/1422-0067/20/16/3844 |
work_keys_str_mv |
AT yukoiwata blockadeoftrpv2isanoveltherapyforcardiomyopathyinmusculardystrophy AT tsuyoshimatsumura blockadeoftrpv2isanoveltherapyforcardiomyopathyinmusculardystrophy |
_version_ |
1725227735563894784 |